Payment overview · 2025
General Payments
$517.60
24 reported records · 13 companies
Healthcare provider profile · identity verified
William Nassour, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GOODYEAR, AZ · NPI 1104131820
Verified facts
What the public records show
CMS Open Payments records show William Nassour, MD received $517.60 in general payments during 2025 across 24 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Zenpep by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 973 claims for Eliquis by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abilify Maintena by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.96 | 16.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $81.79 | 15.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.44 | 12.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $56.42 | 10.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.88 | 8.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $41.29 | 8.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.57 | 5.5% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $27.92 | 5.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.60 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.26 | 3.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.33 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.14 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.00 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $517.60 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $147.40 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $81.79 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $56.42 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
973 | 134 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1234 | 291 |
| Eliquis | Apixaban | 973 | 134 |
| Gabapentin | Gabapentin | 973 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 714 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 695 | 171 |
| Tamsulosin Hcl | Tamsulosin Hcl | 505 | 117 |
| Trazodone Hcl | Trazodone Hcl | 503 | 152 |
| Lisinopril | Lisinopril | 476 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 465 | 110 |
| Furosemide | Furosemide | 451 | 145 |
| Metformin Hcl | Metformin Hcl | 412 | 114 |
| Potassium Chloride | Potassium Chloride | 394 | 95 |
| Sertraline Hcl | Sertraline Hcl | 376 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 93 |
| Carvedilol | Carvedilol | 321 | 83 |
| Levetiracetam | Levetiracetam | 309 | 67 |
| Baclofen | Baclofen | 280 | 62 |
| Divalproex Sodium | Divalproex Sodium | 277 | 73 |
| Losartan Potassium | Losartan Potassium | 277 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 265 | 81 |
| Mirtazapine | Mirtazapine | 263 | 64 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 254 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 65 |
| Donepezil Hcl | Donepezil Hcl | 231 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 72 |
| Ondansetron Hcl | Ondansetron Hcl | 183 | 68 |
| Memantine Hcl | Memantine Hcl | 180 | 40 |
| Midodrine Hcl | Midodrine Hcl | 177 | 66 |
| Benztropine Mesylate | Benztropine Mesylate | 175 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 174 | 57 |
| Risperidone | Risperidone | 168 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 42 |
| Buspirone Hcl | Buspirone Hcl | 163 | 45 |
| Enoxaparin Sodium | Enoxaparin Sodium | 163 | 37 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 161 | 62 |
| Methocarbamol | Methocarbamol | 161 | 37 |
| Simvastatin | Simvastatin | 156 | 34 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 153 | 79 |
| Bumetanide | Bumetanide | 150 | 35 |
| Montelukast Sodium | Montelukast Sodium | 146 | 31 |
| Lactulose | Lactulose | 138 | 49 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 137 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 43 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 128 | 72 |
| Sodium Chloride | 0.9 % Sodium Chloride | 121 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 59 |
| Amiodarone Hcl | Amiodarone Hcl | 119 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 39 |
| Insulin Lispro | Insulin Lispro | 117 | 50 |
| Bupropion Xl | Bupropion Hcl | 115 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 111 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 23 |
| Prednisone | Prednisone | 109 | 50 |
| Spironolactone | Spironolactone | 107 | 30 |
| Famotidine | Famotidine | 104 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 46 |
| Finasteride | Finasteride | 99 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 27 |
| Allopurinol | Allopurinol | 92 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 92 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 35 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 86 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 19 |
| Nifedipine Er | Nifedipine | 82 | 29 |
| Clonidine Hcl | Clonidine Hcl | 78 | 27 |
| Olanzapine | Olanzapine | 77 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 24 |
| Albuterol Sulfate | Albuterol Sulfate | 72 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 18 |
| Propranolol Hcl | Propranolol Hcl | 69 | 23 |
| Amantadine | Amantadine Hcl | 68 | 11 |
| Aripiprazole | Aripiprazole | 68 | 21 |
| Glipizide | Glipizide | 68 | 22 |
| Oxcarbazepine | Oxcarbazepine | 67 | 11 |
| Atenolol | Atenolol | 66 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 66 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 11 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 44 |
| Jardiance | Empagliflozin | 60 | 17 |
| Lamotrigine | Lamotrigine | 60 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 60 | 12 |
| Budesonide | Budesonide | 55 | 21 |
| Vancomycin Hcl | Vancomycin Hcl | 54 | 25 |
| Farxiga | Dapagliflozin Propanediol | 52 | 12 |
| Omeprazole | Omeprazole | 51 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 43 |
| Heparin Sodium | Heparin Sodium,porcine | 50 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 49 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 33 |
| Terazosin Hcl | Terazosin Hcl | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | 17 |
| Gemtesa | Vibegron | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | 19 |
| Topiramate | Topiramate | 44 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 15 |
| Digoxin | Digoxin | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 17 |
| Movantik | Naloxegol Oxalate | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | 20 |
| Clozapine | Clozapine | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 13 |
| Torsemide | Torsemide | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 19 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 17 |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Cephalexin | Cephalexin | 33 | 31 |
| Dalfampridine Er | Dalfampridine | 33 | suppressed |
| Nystatin | Nystatin | 33 | 26 |
| Ozempic | Semaglutide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Admelog Solostar | Insulin Lispro | 32 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Humalog | Insulin Lispro | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Xifaxan | Rifaximin | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 26 |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 20 |
| Haloperidol | Haloperidol | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 18 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 29 | 16 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 12 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | 11 |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Tivicay | Dolutegravir Sodium | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Teriflunomide | Teriflunomide | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 18 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Daptomycin | Daptomycin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nyamyc | Nystatin | 21 | 18 |
| Amiloride Hcl | Amiloride Hcl | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | 11 |
| Meropenem | Meropenem | 20 | 12 |
| Permethrin | Permethrin | 20 | 19 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | 14 |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 15 |
| Abilify Maintena | Aripiprazole | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 17 | suppressed |
| Fetroja | Cefiderocol Sulfate Tosylate | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | 11 |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Acetylcysteine | Acetylcysteine | 16 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 16 | suppressed |
| Briviact | Brivaracetam | 16 | suppressed |
| Corlanor | Ivabradine Hcl | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Epogen | Epoetin Alfa | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Deferasirox | Deferasirox | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $517.60 · 24 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, Auvelity, Briviact, CAPLYTA, COBENFY, IBSRELA, INTELLIS ADAPTIVESTIM, Kerendia, OCTRODE, REXULTI, ROXYBOND, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error